PubRank

Hisashi Ishida

Author PubWeight™ 36.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006 4.84
2 The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 2010 2.00
3 Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010 1.83
4 The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010 1.50
5 Delayed-onset caspase-dependent massive hepatocyte apoptosis upon Fas activation in Bak/Bax-deficient mice. Hepatology 2011 1.47
6 Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2011 1.43
7 Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 2011 1.42
8 A method for the analysis of domain movements in large biomolecular complexes. Proteins 2009 1.24
9 Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 2009 1.12
10 Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli. J Biol Chem 2003 1.11
11 BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 2011 1.08
12 Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology 2013 1.07
13 Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 2008 1.07
14 Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010 1.03
15 Hepatitis C virus core functions as a suppressor of cyclin-dependent kinase-activating kinase and impairs cell cycle progression. J Biol Chem 2004 1.00
16 Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012 0.92
17 Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009 0.92
18 Global conformational changes of ribosome observed by normal mode fitting for 3D Cryo-EM structures. Structure 2009 0.91
19 The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol 2011 0.89
20 Intravenous injection of naked plasmid DNA encoding hepatitis B virus (HBV) produces HBV and induces humoral immune response in mice. Biochem Biophys Res Commun 2003 0.88
21 BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. Hepatology 2009 0.87
22 Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. J Virol 2013 0.85
23 Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus. J Infect Dis 2008 0.82
24 Suppressive effects of Okinawan food items on free radical generation from stimulated leukocytes and identification of some active constituents: implications for the prevention of inflammation-associated carcinogenesis. Asian Pac J Cancer Prev 2006 0.81
25 Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunol Immunother 2012 0.80
26 Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B. Hepatol Res 2012 0.79
27 Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice. Biochem Biophys Res Commun 2011 0.79
28 Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. J Gastroenterol 2011 0.77
29 Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. Antivir Ther 2009 0.77
30 Alteration in gene expression profile by full-length hepatitis B virus genome. Intervirology 2005 0.76
31 Interferon-α suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway. Virology 2012 0.76
32 Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with colon involvement. Can J Gastroenterol Hepatol 2015 0.75
33 Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. J Med Virol 2009 0.75
34 A case report of a duodenal adenocarcinoma: a complication with Crohn's disease. Nihon Shokakibyo Gakkai Zasshi 2016 0.75
35 Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion. Biochem Biophys Res Commun 2010 0.75
36 Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis. Acta Med Okayama 2016 0.75
37 Alterations in hepatitis B virus nucleotide sequences in a chronic virus carrier from immunotolerant to immunoactive phase. Biochem Biophys Res Commun 2010 0.75
38 Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV. Nihon Shokakibyo Gakkai Zasshi 2016 0.75